DCPH News and Press, Deciphera Pharmaceuticals Inc. From 06/03/20

In the last decade alone, scientists have made notable progress understanding cancer progression and developing targeted treatments that significantly improve outcomes. One of the best examples is gastrointestinal stromal tumors (GIST).  As recently as the late 1990s, doctors knew relative...

-Combination of Rebastinib and Paclitaxel Demonstrates Encouraging Anti-tumor Activity and Favorable Tolerability in Patients with Advanced Endometrial Cancer- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of data from the endometrial cancer cohort of P...

-Patients Receiving QINLOCK for Fourth-line GIST Reported Improved Quality of Life and Better Physical and Role Functioning Compared with a Decline in Placebo- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of quality of life and certain safety results f...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2...

Deciphera Pharmaceuticals (NASDAQ: DCPH) , a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since. As of midday Friday, the biopharma's stock is now nearly $8 higher than it was at the end of the previous week -...

Deciphera Receives FDA Approval for GIST Therapy Deciphera Pharmaceuticals ( DCPH ) reported that it has received an early FDA approval for Qinlock for treating patients with gastrointestinal stromal tumor (GIST). The treatment is specifically targeted at patients who did not response to...

-QINLOCK Significantly Improved Progression-Free Survival and Showed Clinically Meaningful Overall Survival in INVICTUS Phase 3 Study- -NDA Approved 3 Months Prior to Action Date Under FDA’s Real Time Oncology Review (RTOR)- -Deciphera to Host Conference Call Today at 5:0...

The FDA approves Deciphera Pharmaceuticals' ( DCPH +6.7% ) ripretinib, branded as Qinlock, for the fourth-line treatment of gastrointestinal stromal tumor (GIST). More news on: Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Nasdaq has suspended trading in Deciphera Pharmaceuticals ( DCPH +6.6% ) pending the release of news. More news on: Deciphera Pharmaceuticals, Inc., Blueprint Medicines Corporation, Healthcare stocks news, Stocks on the move, Read more ...

Blueprint Medicines (NASDAQ: BPMC ) reports that it has received a Complete Response Letter (CRL) from the FDA regarding its marketing application for avapritinib in fourth-line gastrointestinal tumor (GIST). More news on: Blueprint Medicines Corporation, Bayer Aktiengesellschaft, Deciph...